By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login

Ildong Pharmaceutical Co., Ltd. (249420.KS)

KSC Currency in KRW
₩23.80K
+₩2.15K
+9.93%
Last Update: 10 Sept 2025, 06:30
₩735.02B
Market Cap
-55.73
P/E Ratio (TTM)
Forward Dividend Yield
₩10.30K - ₩25.75K
52 Week Range

249420.KS Stock Price Chart

Explore Ildong Pharmaceutical Co., Ltd. interactive price chart. Choose custom timeframes to analyze 249420.KS price movements and trends.

249420.KS Company Profile

Discover essential business fundamentals and corporate details for Ildong Pharmaceutical Co., Ltd. (249420.KS) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

31 Aug 2016

Employees

1.03K

CEO

Yun Paul Woongsup

Description

Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-histamine drugs, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, topical preparation, and urogenital system applications. It also provides raw material drugs; health foods and foods; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products. In addition, the company manages licenses and provides contract manufacturing services. It also exports its products to approximately 20 countries worldwide. Ildong Pharmaceutical Co., Ltd. a strategic collaboration with Evotec SE to accelerate the development of various Ildong's proprietary projects through access to Evotec's INDiGO platform. The company was founded in 1941 and is headquartered in Seoul, South Korea.

249420.KS Financial Timeline

Browse a chronological timeline of Ildong Pharmaceutical Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.

Earnings released on 30 Jun 2025

EPS came in at -₩107.59 , while revenue for the quarter reached ₩138.48B .

Earnings released on 12 May 2025

EPS came in at ₩36.79 , while revenue for the quarter reached ₩135.98B .

Earnings released on 3 Feb 2025

EPS came in at ₩268.31 , while revenue for the quarter reached ₩155.74B , missing expectations by -5.58%.

Earnings released on 30 Oct 2024

EPS came in at -₩335.83 , while revenue for the quarter reached ₩155.95B , missing expectations by -4.30%.

Earnings released on 31 Jul 2024

EPS came in at -₩115.96 , while revenue for the quarter reached ₩152.15B , missing expectations by -5.82%.

Earnings released on 9 May 2024

EPS came in at -₩29.83 , while revenue for the quarter reached ₩151.10B , missing expectations by -0.20%.

Earnings released on 8 Feb 2024

EPS came in at ₩50.69 , while revenue for the quarter reached ₩151.08B , beating expectations by +2.15%.

Earnings released on 6 Nov 2023

EPS came in at -₩1.71K , while revenue for the quarter reached ₩149.53B , missing expectations by -29.13%.

Earnings released on 9 Aug 2023

EPS came in at -₩892.53 , while revenue for the quarter reached ₩154.09B , missing expectations by -14.40%.

Earnings released on 15 May 2023

EPS came in at -₩403.99 , while revenue for the quarter reached ₩146.06B , missing expectations by -11.48%.

Earnings released on 9 Feb 2023

EPS came in at -₩2.01K , while revenue for the quarter reached ₩151.93B , missing expectations by -8.47%.

Earnings released on 24 Oct 2022

EPS came in at -₩626.00 surpassing the estimated -₩1.15K by +45.52%, while revenue for the quarter reached ₩163.63B , beating expectations by +2.14%.

Earnings released on 27 Jul 2022

EPS came in at ₩1.89K surpassing the estimated -₩892.00 by +311.32%, while revenue for the quarter reached ₩162.50B , beating expectations by +0.31%.

Earnings released on 31 Mar 2022

EPS came in at -₩4.86K , while revenue for the quarter reached ₩159.65B .

Earnings released on 17 Feb 2022

EPS came in at -₩3.94K , while revenue for the quarter reached ₩142.70B .

Earnings released on 3 Nov 2021

EPS came in at -₩354.00 , while revenue for the quarter reached ₩142.51B .

Earnings released on 29 Jul 2021

EPS came in at ₩128.00 surpassing the estimated -₩84.96 by +250.66%, while revenue for the quarter reached ₩141.64B .

Earnings released on 17 May 2021

EPS came in at -₩542.00 falling short of the estimated -₩33.13 by -1.54K%, while revenue for the quarter reached ₩133.27B .

Earnings released on 19 Feb 2021

EPS came in at -₩795.58 , while revenue for the quarter reached ₩138.76B .

Earnings released on 16 Nov 2020

EPS came in at ₩38.00 , while revenue for the quarter reached ₩146.82B .

249420.KS Stock Performance

Access detailed 249420.KS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run